DGIdb - ABEXINOSTAT Drug Record

ABEXINOSTAT chembl:CHEMBL2103863 Antineoplastic

Alternate Names:

PCI 24781
CRA-024781
S-78454
CRA 024781
PCI-24781
PZP115891
CRA 24781
ABEXINOSTAT
PZP-115891
chemidplus:783355-60-2
drugbank:12565
pubchem.compound:11749858
chembl:CHEMBL2103863

Drug Info:

FDA Approval	not approved
Drug Class	Small molecule
Drug Indications	antineoplastic agent

(2 More Sources)

Publications:

Aggarwal R et al., 2017, Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies., J Clin Oncol

ABEXINOSTAT HDAC2

Interaction Score: 0.58

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name PCI-27483, CRA-024781

Novel drug target Established target

Notes

PMIDs:
28221861

Sources:
TALC TdgClinicalTrial CIViC
ABEXINOSTAT HDAC10

Interaction Score: 0.34

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name PCI-27483, CRA-024781

Novel drug target Established target

PMIDs:
None found

Sources:
TALC TdgClinicalTrial
ABEXINOSTAT HDAC3

Interaction Score: 0.3

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name PCI-27483, CRA-024781

Novel drug target Established target

Notes

PMIDs:
None found

Sources:
TALC TdgClinicalTrial
ABEXINOSTAT HDAC6

Interaction Score: 0.29

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name PCI-27483, CRA-024781

Novel drug target Established target

PMIDs:
None found

Sources:
TALC TdgClinicalTrial
ABEXINOSTAT HDAC1

Interaction Score: 0.24

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name PCI-27483, CRA-024781

Novel drug target Established target

Notes

PMIDs:
None found

Sources:
TALC TdgClinicalTrial
ABEXINOSTAT HDAC9

Interaction Score: 0.18

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC
ABEXINOSTAT HDAC5

Interaction Score: 0.16

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC
ABEXINOSTAT HDAC7

Interaction Score: 0.16

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC
ABEXINOSTAT HDAC8

Interaction Score: 0.15

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC
ABEXINOSTAT HDAC4

Interaction Score: 0.14

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC
ABEXINOSTAT HTT

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD

TdgClinicalTrial: CRA-024781
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:

CIViC: ABEXINOSTAT

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Aggarwal R et al., 2017, Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies., J Clin Oncol

TALC: PCI-24781
- Version: 12-May-2016
Alternate Names:

PCI-24781 Primary Drug Name

PCI-24781 Drug Synonym

Drug Info:

Publications:
TTD: Abexinostat
- Version: 2020.06.01
Alternate Names:

D0V0SL TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL2103863
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
MyCancerGenomeClinicalTrial: PCI-24781
- Version: 30-February-2014
Alternate Names:

Drug Info:

Publications:

Trial Name	PCI-27483, CRA-024781
Novel drug target	Established target
Notes

ABEXINOSTAT Drug Record

ABEXINOSTAT chembl:CHEMBL2103863 Antineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name PCI-27483, CRA-024781 Novel drug target Established target Notes

PMIDs: 28221861

Sources: TALC TdgClinicalTrial CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name PCI-27483, CRA-024781 Novel drug target Established target

PMIDs: None found

Sources: TALC TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name PCI-27483, CRA-024781 Novel drug target Established target Notes

PMIDs: None found

Sources: TALC TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name PCI-27483, CRA-024781 Novel drug target Established target

PMIDs: None found

Sources: TALC TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name PCI-27483, CRA-024781 Novel drug target Established target Notes

PMIDs: None found

Sources: TALC TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: None found

Sources: TALC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: None found

Sources: TALC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: None found

Sources: TALC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: None found

Sources: TALC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: None found

Sources: TALC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

TdgClinicalTrial: CRA-024781

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class Small molecule FDA Approval not approved

Publications:

CIViC: ABEXINOSTAT

Alternate Names:

Drug Info:

Publications: Aggarwal R et al., 2017, Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies., J Clin Oncol

TALC: PCI-24781

Alternate Names: PCI-24781 Primary Drug Name PCI-24781 Drug Synonym

Drug Info:

Publications:

TTD: Abexinostat

Alternate Names: D0V0SL TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL2103863

Alternate Names:

Drug Info:

Publications:

MyCancerGenomeClinicalTrial: PCI-24781

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name PCI-27483, CRA-024781

Novel drug target Established target

Notes

PMIDs:
28221861

Sources:
TALC TdgClinicalTrial CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name PCI-27483, CRA-024781

Novel drug target Established target

PMIDs:
None found

Sources:
TALC TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name PCI-27483, CRA-024781

Novel drug target Established target

Notes

PMIDs:
None found

Sources:
TALC TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name PCI-27483, CRA-024781

Novel drug target Established target

PMIDs:
None found

Sources:
TALC TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name PCI-27483, CRA-024781

Novel drug target Established target

Notes

PMIDs:
None found

Sources:
TALC TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:

Aggarwal R et al., 2017, Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies., J Clin Oncol

Alternate Names:

PCI-24781 Primary Drug Name

PCI-24781 Drug Synonym

Alternate Names:

D0V0SL TTD Drug ID